Mebendazole Shows Antiproliferative Activity in Childhood Low-Grade Brain Tumor Models (2026)
A June 2026 preclinical study from Rome found mebendazole significantly inhibited cell growth and migration in two pediatric low-grade glioma cell lines, supporting its potential as a repositioned therapeutic drug.
By Sanare Lab · July 31, 2026 · 6 min read
Key Takeaway
A June 2026 study from Catholic University Medical School in Rome found that mebendazole (MBZ) — a common antiparasitic drug — significantly inhibited cell growth and migration in two pediatric low-grade glioma cell lines. The findings support mebendazole as a candidate for drug repositioning in children's brain tumors, though the research remains at the preclinical (cell culture) stage.
A June 2026 study from Catholic University Medical School in Rome tested mebendazole, a common drug for intestinal worm infections, on pediatric low-grade glioma cells, which come from children’s brain tumors. In two pediatric low-grade glioma cell lines (cells grown in a lab), mebendazole significantly slowed cell growth and movement. The results suggest mebendazole could be studied for drug repositioning (using an existing drug for a new disease), but this was only preclinical cell-culture research and is not an available treatment for children’s brain tumors.
Pediatric low-grade gliomas (pLGG) are the most common brain tumors in children, accounting for roughly 30–40% of all pediatric central nervous system tumors. While many children respond well to initial treatment, a significant subset experience recurrence or progressive disease that requires additional therapy. Conventional chemotherapy carries substantial long-term toxicity risks in young patients, making the search for better-tolerated alternatives a clinical priority.
Mebendazole, an inexpensive anthelmintic drug used for decades to treat intestinal worm infections, has attracted growing scientific interest as a potential anticancer agent. Its ability to disrupt microtubule dynamics — the same mechanism that makes it effective against parasites — also interferes with cancer cell division. A new 2026 study from Rome's Fondazione Policlinico Universitario A. Gemelli-IRCCS now adds pediatric low-grade glioma to the list of tumor types where mebendazole shows preclinical promise.
The study, published in Oncology Research (June 2026), was conducted by researchers from the Section of Pharmacology and the Pediatric Oncology Unit at Catholic University Medical School. It evaluated mebendazole's antiproliferative and anti-migratory effects in two established pediatric glioma cell lines (RES 259 and RES 186), and also explored whether combining mebendazole with vinblastine — a standard chemotherapy agent — could produce synergistic effects.
Table of Contents
- Study Background
- What the Researchers Found
- Why the Combination Did Not Work
- Evidence Level and Limitations
- What This Means for Patients
- FAQ
- Shop Sanare Lab
- References
Study Background
Pediatric low-grade gliomas are biologically distinct from adult gliomas and from pediatric high-grade gliomas. They are typically driven by BRAF alterations (most commonly the KIAA1549-BRAF fusion) and generally have a favorable prognosis — but recurrent or progressive cases present a significant therapeutic challenge. Targeted therapies (MEK inhibitors, BRAF inhibitors) have improved outcomes, yet drug resistance and long-term toxicity remain concerns.
Mebendazole's anticancer mechanism centers on its ability to bind tubulin and prevent microtubule polymerization, thereby blocking mitosis. This is the same mechanism exploited by established chemotherapy agents such as vincristine and vinblastine. However, mebendazole has a distinct binding profile and may affect different tubulin isoforms, which could give it a unique activity spectrum in tumor cells.
| Parameter | Detail |
|---|---|
| Study type | Preclinical — in vitro cell culture |
| Cancer type | Pediatric low-grade glioma |
| Cell lines | RES 259 and RES 186 (human pediatric glioma) |
| Institution | Catholic University Medical School / Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy |
| Published | Oncology Research, June 16, 2026 |
| DOI | 10.32604/or.2026.071074 |
What the Researchers Found
After 48 hours of mebendazole treatment, both RES 259 and RES 186 cell lines showed significant cytotoxicity and inhibited cell growth. Importantly, mebendazole also demonstrated anti-migratory activity — meaning it reduced the ability of glioma cells to invade surrounding tissue, a key factor in tumor progression. The drug disrupted MAP kinase signaling, a pathway involved in cell proliferation and survival that is frequently dysregulated in pediatric gliomas.
| Effect Observed | Cell Line | Result |
|---|---|---|
| Cytotoxicity (48h) | RES 259 & RES 186 | Significant cell death induced |
| Cell growth inhibition | Both lines | Significantly inhibited |
| Anti-migratory effect | Both lines | Demonstrated (reduced invasion) |
| MAP kinase signaling | Both lines | Disrupted |
| MBZ + vinblastine synergy | Both lines | No synergistic or additive effect |
Why the Combination Did Not Work
One of the study's notable findings was that combining mebendazole with vinblastine did not produce synergistic or additive anticancer effects. The researchers attribute this to the fact that both drugs target microtubule dynamics — mebendazole by inhibiting tubulin polymerization, and vinblastine by binding to tubulin and preventing microtubule assembly. When two drugs share the same molecular target, combining them often fails to produce additional benefit and may even lead to competitive interference.
This finding has practical implications for future clinical trial design: mebendazole should likely be tested as a single agent or combined with drugs that work through complementary, non-overlapping mechanisms — such as BRAF/MEK inhibitors, which are already used in pediatric glioma treatment.
Evidence Level and Limitations
This study is preclinical — all experiments were conducted in cell culture (in vitro), not in animals or humans. While the results are promising, they cannot be directly extrapolated to clinical outcomes. Key limitations include:
- No animal (in vivo) experiments were performed in this study
- Only two cell lines were tested; pediatric gliomas are biologically heterogeneous
- Optimal dosing, pharmacokinetics, and blood-brain barrier penetration in children were not assessed
- No clinical trial data exists specifically for mebendazole in pediatric low-grade glioma
Mebendazole has been studied in adult glioblastoma (high-grade) in early-phase clinical trials, including a Johns Hopkins trial, but pediatric low-grade glioma represents a distinct and underexplored indication. This study is one of the first to specifically address this gap.
What This Means for Patients and Families
For families of children with low-grade glioma, this research adds to a growing body of evidence that mebendazole may have a role in pediatric brain tumor treatment. However, it is critical to understand that preclinical cell-culture data does not confirm clinical efficacy or safety in children. Mebendazole is not approved for cancer treatment in any country, and its use outside of clinical trials carries unknown risks.
The appropriate next step would be animal model studies followed by carefully designed pediatric clinical trials. Families interested in mebendazole should discuss the current evidence with their child's oncologist before considering any off-label use.
For background, see our guide to how fenbendazole compares with mebendazole.
We cover this in more depth in our article on fenbendazole in brain cancer and glioblastoma.
Estimate a weight-based regimen with our protocol calculator.
Frequently Asked Questions
Frequently Asked Questions
What is mebendazole and how does it work against cancer?
Mebendazole is an antiparasitic drug that kills worms by disrupting their microtubule function. In cancer cells, it works through the same mechanism — binding to tubulin and preventing cell division. It also disrupts MAP kinase signaling, which is involved in cancer cell survival and proliferation.
What type of glioma was studied in this 2026 research?
The study focused on pediatric low-grade glioma (pLGG), which is distinct from adult glioblastoma (GBM) and from pediatric high-grade glioma. Low-grade gliomas are generally slower-growing but can recur and become difficult to treat.
Did mebendazole work in combination with vinblastine?
No. The study found that combining mebendazole with vinblastine did not produce synergistic or additive effects. Both drugs target microtubule dynamics, so combining them did not provide additional benefit. The researchers suggest exploring mebendazole as a single agent or with drugs that have different mechanisms.
Is this research ready for clinical use in children?
No. This is a preclinical study conducted in cell cultures only. There are no clinical trials of mebendazole specifically for pediatric low-grade glioma. Clinical use would require animal studies and then carefully designed pediatric trials before any conclusions about safety or efficacy in children can be drawn.
Has mebendazole been studied in any brain tumor clinical trials?
Yes, but in adult glioblastoma (high-grade), not pediatric low-grade glioma. A Johns Hopkins early-phase trial evaluated mebendazole in adult GBM patients. This 2026 study is among the first to specifically investigate mebendazole in pediatric low-grade glioma cell models.
Where was this study conducted?
The study was conducted at the Catholic University Medical School and Fondazione Policlinico Universitario A. Gemelli-IRCCS in Rome, Italy, by researchers from the Section of Pharmacology and the Pediatric Oncology Unit.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
180 capsules — 99% purity, laboratory tested
180 capsules — higher-dose option
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Ferraro C, Pizzoferrato M, Graziano M, Servidei T, Ruggiero A, Navarra P, Lisi L. Mebendazole Shows Antiproliferative and Antimigratory Effects in Paediatric Low-Grade Glioma Models. Oncol Res. 2026 Jun 16;34(7):16. doi: 10.32604/or.2026.071074. PMID: 42358840.
- Pham TN, Stempel S, Shields MA, et al. Mebendazole Inhibits the Growth of Glioblastoma Multiforme. J Neurooncol. 2021. doi: 10.1007/s11060-021-03726-0.
- Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011;13(9):974-982.
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.